相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials
Shomron Ben-Horin et al.
GASTROENTEROLOGY (2022)
Decision Support Tool Identifies Ulcerative Colitis Patients Most Likely to Achieve Remission With Vedolizumab vs Adalimumab
Parambir S. Dulai et al.
INFLAMMATORY BOWEL DISEASES (2022)
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials
Silvio Danese et al.
LANCET (2022)
Modified Mayo score versus Mayo score for evaluation of treatment efficacy in patients with ulcerative colitis: data from the tofacitinib OCTAVE program
William J. Sandborn et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2022)
Incidence of and Risk Factors for Colorectal Strictures in Ulcerative Colitis: A Multicenter Study
Pierre-Antoine Laurain et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)
Selecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT Consensus From the IOIBD
Catherine Le Berre et al.
GASTROENTEROLOGY (2021)
Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY)
Laurent Peyrin-Biroulet et al.
GASTROENTEROLOGY (2021)
An International Consensus to Standardize Integration of Histopathology in Ulcerative Colitis Clinical Trials
Christopher Ma et al.
GASTROENTEROLOGY (2021)
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
Dan Turner et al.
GASTROENTEROLOGY (2021)
Validation and Update of the Lemann Index to Measure Cumulative Structural Bowel Damage in Crohn's Disease
Benjamin Pariente et al.
GASTROENTEROLOGY (2021)
Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial
Brian G. Feagan et al.
LANCET (2021)
Ulcerative Colitis and Crohn's Disease Have Similar Burden and Goals for Treatment
Catherine Le Berre et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis
Parambir S. Dulai et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
Incremental Benefit of Achieving Endoscopic and Histologic Remission in Patients With Ulcerative Colitis: A Systematic Review and Meta-Analysis
Hyuk Yoon et al.
GASTROENTEROLOGY (2020)
Evaluating the optimum number of biopsies to assess histological inflammation in ulcerative colitis: a retrospective cohort study
Robert Battat et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
B. E. Sands et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Shorter Disease Duration Is Associated With Higher Rates o f Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis
David M. Faleck et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
Fibrosis in ulcerative colitis is directly linked to severity and chronicity of mucosal inflammation
I. O. Gordon et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium
Neeraj Narula et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2018)
Development and validation of a histological index for UC
Mahmoud H. Mosli et al.
GUT (2017)
A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab
Maria Rosario et al.
CLINICAL PHARMACOKINETICS (2017)
Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study
A. Stallmach et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
Similar Clinical and Surgical Outcomes Achieved with Early Compared to Late Anti-TNF Induction in Mild-to-Moderate Ulcerative Colitis: A Retrospective Cohort Study
Christopher Ma et al.
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2016)
Extent of Early Clinical Response to Infliximab Predicts Long-term Treatment Success in Active Ulcerative Colitis
Sanjay K. Murthy et al.
INFLAMMATORY BOWEL DISEASES (2015)
Decreasing trends in hospitalizations during anti-TNF therapy are associated with time to anti-TNF therapy: Results from two referral centres
Michael D. Mandel et al.
DIGESTIVE AND LIVER DISEASE (2014)
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Brian G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Development of the Paris Definition of Early Crohn's Disease for Disease-Modification Trials: Results of an International Expert Opinion Process
Laurent Peyrin-Biroulet et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2012)
Risk of Colorectal Cancer in Patients With Ulcerative Colitis: A Meta-analysis of Population-Based Cohort Studies
Tine Jess et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2012)
A Multicenter Experience With Infliximab for Ulcerative Colitis: Outcomes and Predictors of Response, Optimization, Colectomy, and Hospitalization
Abderrahim Oussalah et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study)
Inger Camilla Solberg et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2009)
A reproducible grading scale for histological assessment of inflammation in ulcerative colitis
K Geboes et al.
GUT (2000)
分享论文
